Form 4: Arcturus Therapeutics Director Jing L. Marantz Reports Stock Transactions

Director Jing L. Marantz reports acquisition of stock options and disposal of deferred stock units in Arcturus Therapeutics.

Summary

• On June 14, 2024, Jing L. Marantz, a director of Arcturus Therapeutics Holdings Inc., reported transactions involving the company's stock.
• Marantz acquired 15,000 stock options with an exercise price of $31, vesting monthly over one year and expiring on June 14, 2034.
• Additionally, 3,131 deferred stock units were disposed of, each equivalent to one share of common stock, as part of the 2023 annual grant that vested on June 14, 2024.
• Following these transactions, Marantz beneficially owns 15,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports routine stock transactions by a company director.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future performance.

Future Outlook

The stock options vest monthly over a one-year period from the date of grant, suggesting a continued alignment of the director's interests with the company's performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track potential shifts in ownership and sentiment.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of company insiders.

Key Dates